212 related articles for article (PubMed ID: 187312)
1. Combination chemotherapy of advanced lung cancer: a randomized trial.
Hansen HH; Selawry OS; Simon R; Carr DT; van Wyk CE; Tucker RD; Sealy R
Cancer; 1976 Dec; 38(6):2201-7. PubMed ID: 187312
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine.
Alberto P; Brunner KW; Martz G; Obrecht J; Sonntag RW
Cancer; 1976 Dec; 38(6):2208-16. PubMed ID: 187313
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
McMahon LJ; Jones SE; Durie BG; Salmon SE
Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors in the chemotherapy of bronchial cancers].
Alberto P
Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
[No Abstract] [Full Text] [Related]
5. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
Stolinsky DC; Bull FE; Pajak TF; Bateman JR
Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.
Hansen HH; Dombernowsky P; Hansen M; Hirsch F
Ann Intern Med; 1978 Aug; 89(2):177-81. PubMed ID: 209710
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
[No Abstract] [Full Text] [Related]
8. Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.
Chahinian PA; Arnold DJ; Cohen JM; Purpora DP; Jaffrey IS; Teirstein AS; Kirschner PA; Holland JF
JAMA; 1977 May; 237(22):2392-6. PubMed ID: 576939
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of bronchogenic carcinomas by a combination of cyclophosphamide, methotrexate, vincristin and bleomycin.
Schaerer R; Sotto JJ; Wiget U; Perdrix A; Bensa JC; Ribaud P
Eur J Cancer (1965); 1977; 13(4-5):425-8. PubMed ID: 68881
[No Abstract] [Full Text] [Related]
10. MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
Chahinian AP; Mandel EM; Holland JF; Jaffrey IS; Teirstein AS
Cancer; 1979 May; 43(5):1590-7. PubMed ID: 221093
[No Abstract] [Full Text] [Related]
11. CCNU-adriamycin therapy in bronchogenic carcinoma.
Trowbridge RC; Kennedy BJ; Vosika GJ
Cancer; 1978 May; 41(5):1704-9. PubMed ID: 206337
[TBL] [Abstract][Full Text] [Related]
12. A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
Alberto P; Barrelet L; Chapuis B; Garcia B
Eur J Cancer (1965); 1975 Nov; 11(11):795-9. PubMed ID: 767111
[No Abstract] [Full Text] [Related]
13. Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung.
Dombernowsky P; Hansen HH
Acta Med Scand; 1978; 204(6):513-6. PubMed ID: 216239
[TBL] [Abstract][Full Text] [Related]
14. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of extensive large cell and adenocarcinoma of the lung: a randomized trial in 210 patients.
Vincent RG; Mehta CR; Tucker RD; Mountain CF; Cohen M; Wilson HE; Vogel C
Cancer; 1980 Jul; 46(2):256-60. PubMed ID: 6992978
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
Bitran JD; Desser RK; DeMeester TR; Colman M; Evans R; Billings A; Griem M; Rubenstein L; Shapiro C; Golomb HM
Cancer Treat Rep; 1976 Sep; 60(9):1225-30. PubMed ID: 189920
[TBL] [Abstract][Full Text] [Related]
17. Nitrosourea combinations in lung cancer.
Livingston RB
Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
[TBL] [Abstract][Full Text] [Related]
18. Combined modality treatment for oat cell carcinoma of the lung: a randomized trial 1,2,3.
Alexander M; Glatstein EJ; Gordon DS; Daniels JR
Cancer Treat Rep; 1977; 61(1):1-6. PubMed ID: 193642
[TBL] [Abstract][Full Text] [Related]
19. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
